Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
A phase 3 trial of Cabozantinib in renal cell carcinoma, run by Arcus Biosciences, Inc., now recruiting.
Overview
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma is a phase 3 interventional study registered as NCT07011719 by Arcus Biosciences, Inc., with 720 participants planned, started 2025-09-08 and due to reach its primary completion in 2028-04. Interventions recorded: Casdatifan, Cabozantinib, Placebo. Conditions listed: Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
Shares Cabozantinib, Renal cell carcinoma.
- TargetAXL
Shares Cabozantinib, Renal cell carcinoma.
- TrialA Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal
Shares Cabozantinib, Renal cell carcinoma.
- TrialCOSMIC-313
Shares Cabozantinib, Renal cell carcinoma.
- TrialA Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Shares Cabozantinib, Renal cell carcinoma.
- TargetTIE2 receptor (TEK)
Shares Cabozantinib, Renal cell carcinoma.
- TrialCONTACT-03
Shares Cabozantinib, Renal cell carcinoma.
- TrialCheckMate 9ER
Shares Cabozantinib, Renal cell carcinoma.